Albemarle Corporation $ALB Stock Holdings Increased by GW&K Investment Management LLC

GW&K Investment Management LLC raised its holdings in Albemarle Corporation (NYSE:ALB – Free Report) by 12,206.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,612 shares of the specialty chemicals company’s stock after buying an additional 32,347 shares during the period. GW&K Investment Management LLC’s holdings in Albemarle were worth $3,450,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Private Advisor Group LLC raised its position in shares of Albemarle by 529.2% during the 3rd quarter. Private Advisor Group LLC now owns 27,032 shares of the specialty chemicals company’s stock worth $2,859,000 after acquiring an additional 22,736 shares in the last quarter. Focus Advisor Solutions LLC lifted its stake in Albemarle by 49.9% during the third quarter. Focus Advisor Solutions LLC now owns 5,675 shares of the specialty chemicals company’s stock worth $600,000 after purchasing an additional 1,890 shares during the last quarter. Aegis Wealth Management LLC lifted its stake in Albemarle by 34.8% during the third quarter. Aegis Wealth Management LLC now owns 5,391 shares of the specialty chemicals company’s stock worth $570,000 after purchasing an additional 1,391 shares during the last quarter. Bornite Capital Management LP acquired a new position in Albemarle in the third quarter valued at approximately $15,867,000. Finally, Meeder Asset Management Inc. boosted its holdings in Albemarle by 982.7% in the third quarter. Meeder Asset Management Inc. now owns 1,061 shares of the specialty chemicals company’s stock valued at $112,000 after purchasing an additional 963 shares in the last quarter. 92.87% of the stock is owned by hedge funds and other institutional investors.

Albemarle Stock Down 4.1%

Albemarle stock opened at $79.54 on Friday. Albemarle Corporation has a fifty-two week low of $79.38 and a fifty-two week high of $221.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.57 and a current ratio of 2.34. The company has a market capitalization of $9.39 billion, a P/E ratio of 19.21, a PEG ratio of 0.50 and a beta of 1.34. The stock has a 50-day simple moving average of $99.63 and a 200-day simple moving average of $143.32.

Albemarle (NYSE:ALB – Get Free Report) last announced its earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.52 billion. Albemarle had a return on equity of 14.91% and a net margin of 10.40%. The business’s revenue was up 18.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.19) EPS. Equities research analysts expect that Albemarle Corporation will post 10.64 earnings per share for the current year.

Albemarle Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, December 18th will be issued a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Friday, December 18th. Albemarle’s dividend payout ratio is presently 39.61%.

Analyst Upgrades and Downgrades

Several brokerages have commented on ALB. JPMorgan Chase & Co. dropped their price target on shares of Albemarle from $160.00 to $140.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 25th. Mizuho raised shares of Albemarle from a “neutral” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Wednesday, October 14th. Truist Financial restated a “buy” rating and set a $170.00 price objective (down from $185.00) on shares of Albemarle in a research report on Friday, November 6th. Royal Bank Of Canada lowered their target price on shares of Albemarle from $129.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, November 6th. Finally, UBS Group dropped their target price on shares of Albemarle from $150.00 to $137.00 and set a “buy” rating on the stock in a research report on Monday, November 9th. Fifteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Albemarle has a consensus rating of “Moderate Buy” and an average target price of $152.63.

Read Our Latest Report on ALB

Albemarle Company Profile

(Free Report)

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.

Further Reading

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.